Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

摘要: To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343 treated within trials the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Two hundred eighty-nine belonged to 1 4 major subtypes: anaplastic large cell (ALCL), kinase (ALK)-positive (n = 78); ALCL, ALK-negative 113); peripheral lymphoma, unspecified (PTCLU; n 70); angioimmunoblastic (AITL; 28). Treatment consisted 6-8 courses CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone) or etoposide plus (CHOEP). Three-year event-free survival (EFS) overall were 75.8% 89.8% (ALK-positive ALCL), 50.0% 67.5% (AITL), 45.7% 62.1% (ALK-negative 41.1% 53.9% (PTCLU), respectively. The International Prognostic Index (IPI) was effective in defining risk groups significantly different outcomes. For patients, ≤ 60 years lactate dehydrogenase upper normal value (UNV), improved 3-year EFS: 75.4% versus 51.0%, P .003. In > 6 administered every 3 weeks remains standard therapy. Patients PTCLU, AITL presenting IPI have a poor should be considered candidates for novel treatment strategies.